IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth
IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth
Read moreFri, 03rd Dec 2021 13:23
IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth
Read moreIN BRIEF: Hutchison China Amends License Agreement With Eli Lilly
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.
Read moreChi-Med Trials Dual Inhibitor For Hematological Cancer
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreHutchison China Gets USD100 Million From US Private Equity Firm
Read moreIN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug
Read more(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.
Read more(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.
Read moreUK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser
Read moreUK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service
Read moreUK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks
Read moreUK TRADING UPDATE SUMMARY: New Trend Lifestyle Sees Extended Turmoil
Read moreHutchison China Gets US FDA Fast Track Status For Surufatinib
Read more